Benefits of cocrystallisation in pharmaceutical materials science: an update

被引：197

作者：

Friscic, Tomislav ^{[1
]}

Jones, William ^{[1
]}

机构：

[1] Univ Cambridge, Pfizer Inst Pharmaceut Mat Sci, Cambridge CB2 1EW, England

来源：

JOURNAL OF PHARMACY AND PHARMACOLOGY | 2010年 / 62卷 / 11期

关键词：

crystal structure; materials properties; pharmaceutical cocrystals; solid forms; solubility; stability; IMPROVING MECHANICAL-PROPERTIES; SOLID-STATE CRYSTALLIZATION; CO-CRYSTAL FORMATION; BIS-BETA-NAPHTHOL; HYDROGEN-BOND; MOLECULAR RECOGNITION; 1,1'-BI-2-NAPHTHOL DERIVATIVES; PHYSICOCHEMICAL PROPERTIES; ORGANIC-SYNTHESIS; COMPLEXES;

D O I：

10.1111/j.2042-7158.2010.01133.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objectives We provide a brief overview of recent applications of cocrystals for improving the physico-chemical and materials properties of active pharmaceutical ingredients, including solubility, humidity and thermal stability, dissolution rates and compressibility for tablet formation. Key findings This overview illustrates the pharmaceutical applications of cocrystals, with a selection of recent examples and also attempts to foresee future developments by proposing several directions not yet explored in the area of pharmaceutical cocrystallisation. Summary Reliable strategies for the synthesis and design of pharmaceutical cocrystals have now been established, and the potential of cocrystallisation for enhancing the solid-state properties of drugs is well recognised; the field is now moving towards the understanding of cocrystal structure-property relationships, for which systematic structural studies and computational approaches will play a key role.

引用

页码：1547 / 1559

页数：13

共 90 条

[1]

Aakeröy CB, 2001, ANGEW CHEM INT EDIT, V40, P3240, DOI 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO

[2]

2-X

[3] Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].

Almarsson, Ö ;

Zaworotko, MJ .

CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896

[4] Crystal Forms of the Antibiotic 4-Aminosalicylic Acid: Solvates and Molecular Salts with Dioxane, Morpholine, and Piperazine [J].

Andre, Vania ;

Braga, Dario ;

Grepioni, Fabrizia ;

Duarte, M. Teresa .

CRYSTAL GROWTH & DESIGN, 2009, 9 (12) :5108-5116

[5] Halogen bonds in biological molecules [J].

Auffinger, P ;

Hays, FA ;

Westhof, E ;

Ho, PS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (48) :16789-16794

[6] Applying hot-stage microscopy to co-crystal screening: A study of nicotinamide with seven active pharmaceutical ingredients [J].

Berry, David J. ;

Seaton, Colin C. ;

Clegg, William ;

Harrington, Ross W. ;

Coles, Simon J. ;

Horton, Peter N. ;

Hursthouse, Michael B. ;

Storey, Richard ;

Jones, William ;

Friscic, Tomislav ;

Blagden, Nicholas .

CRYSTAL GROWTH & DESIGN, 2008, 8 (05) :1697-1712

[7] Understanding and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility [J].

Bethune, Sarah J. ;

Huang, Neal ;

Jayasankar, Adivaraha ;

Rodriguez-Hornedo, Nair .

CRYSTAL GROWTH & DESIGN, 2009, 9 (09) :3976-3988

[8] The prediction, morphology, and mechanical properties of the polymorphs of paracetamol [J].

Beyer, T ;

Day, GM ;

Price, SL .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (21) :5086-5094

[9] Co-crystal formation and the determination of absolute configuration [J].

Bhatt, Prashant M. ;

Desiraju, Gautam R. .

CRYSTENGCOMM, 2008, 10 (12) :1747-1749

[10] Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates [J].

Blagden, N. ;

de Matas, M. ;

Gavan, P. T. ;

York, P. .

ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :617-630

← 1 2 3 4 5 6 7 8 9 →